1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMaximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional) is sponsored by National Institutes of Health. Supports individual investigators in biomedical research to enhance funding stability and foster innovative scientific projects.
Get alerted about grants like this
Save a search for “National Institutes of Health” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Maximizing Investigators' Research Award (MIRA) (R35) | National Institute of General Medical Sciences MIRA provides support for research in an investigator's laboratory that falls within the mission of NIGMS . The goal of MIRA is to increase the efficiency of NIGMS funding by providing investigators with greater stability and flexibility, thereby enhancing scientific productivity and the chances for important breakthroughs.
The program will also help distribute funding more widely among the nation's highly talented and promising investigators. MIRA grants will generally be for 5 years, for both established investigators/ new investigators and early stage investigators .
With the publication of PAR-26-121 , the program has now expanded to include established investigators who currently hold an NIGMS R01-equivalent grant or who wish to renew a MIRA, as well as new investigators who are not serving as a subproject leader on any multicomponent awards and propose research in the NIGMS mission. Early stage investigators should apply through PAR-23-145 .
MIRA for Established and New Investigators (EIs and NIs) New NOFO Published: PAR-26-121 See below for MIRA for Early-Stage Investigators (ESIs). PAR-26-121 – Applications accepted in 2026-2028 FAQs About MIRA PAR-22-180 MIRA Eligibility for Administrative Supplements MIRA Eligibility Decision Tree EI and NI MIRA Applicant Slides For more information on MIRA for established investigators contact Ashley Barnes, Ph. D.
, and Baishali Maskeri, Ph. D. , at NIGMS_EINIMIRA@nigms.
nih. gov MIRA for Early Stage Investigators (ESIs) PAR-26-032 – MIRA for ESIs Forecast Announcement FAQs About MIRA PAR-23-145 MIRA ESI Applicant Slides PAR-23-145 - Applications accepted through February 3, 2026 Eligibility: NIH Definitions of Early Stage Investigators and Related Policies and Procedures For more information on MIRA for ESIs contact Michelle R. Bond, Ph.
D. , and Marc Rigas, Ph. D.
, at NIGMS-ESIMIRA@nigms. nih. gov .
Virtual Office Hours - Navigating NIGMS Grants MIRA Awards Reflect Innovation of UConn Scientists ASBMB Today Article on MIRA Program This page last updated on
Based on current listing details, eligibility includes: Public and private institutions of higher education, including universities. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is May 26, 2028. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Purpose. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, enhance and validate translational tools to facilitate rigorous study of complementary and alternative medicine (CAM) approaches that are in wide use by the public. Recent data from the National Health Interview Survey [http://www.cdc.gov/nchs/nhis.htm] establish that Americans are utilizing CAM approaches to promote health and well-being, to treat or prevent disease, and for symptom relief. CAM approaches being widely used include massage and manipulative therapies, meditation, yoga, and acupuncture. Health conditions, particularly chronic pain, back pain and musculoskeletal pain, are the most commonly cited reasons for their use. This FOA focuses on encouraging the development of improved tools to study safety, efficacy, and clinical effectiveness of widely used CAM approaches, such as: mind-body interventions, manual therapies, yoga, and acupuncture. This FOA is not focused on tools for the study of natural products, such as herbal therapies. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, RFA-AT-09-002, which solicits applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 5 projects awarded as a result of this announcement is $1.25 million for fiscal year 2010. Future year amounts will depend on annual appropriations. Funding Opportunity Number: RFA-AT-09-004. Assistance Listing: 93.213. Funding Instrument: G. Category: HL. Award Amount: $1.3M total program funding.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
-This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the modification or development of new screening technologies that are better able to consistently detect mild hearing loss (i.e., less than 40 dB Hearing Level or 40 dB HL) in one or both ears in infants and young children without significantly increasing the number of false positives (i.e., those who fail the screen but do not have hearing loss). -The Early Hearing Detection and Intervention (EHDI) program within the National Center for Birth Defects and Developmental Disabilities (NCBDDD) of the Centers for Disease Control and Prevention (CDC) and the National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, are working to ensure infants and children with mild forms of hearing loss are identified as soon as possible. Part of this effort involves having screening technology available that can reliably detect these hearing losses. -This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-06-547, that solicits applications under the Small Business Technology Transfer (STTR [R41/R42]) grant mechanisms. Note,that CDC does not accept STTR applications so is participating only in PA-06-546. Funding Opportunity Number: PA-06-546. Assistance Listing: 93.173,93.283. Funding Instrument: G. Category: HL.